Halozyme Therapeutics (HALO) Adds A New Director, Is It 21% Overvalued?
Halozyme Therapeutics (HALO) recently elected Dannielle Appelhans to its Board of Directors, following strong share price returns, increased revenue, and ongoing buybacks. While analysts generally view HALO as 20.7% overvalued with a fair value of $86.89, a Discounted Cash Flow (DCF) model by Simply …